GreenJay Therapeutics

Executive Summary

GreenJay Therapeutics is a pre-clinical pharmaceutical company based in Cambridge, MA, focused on reformulating existing drugs to improve clinical outcomes. Its lead candidate is a novel intravenous (IV) formulation of busulfan, a chemotherapy agent used as a conditioning treatment prior to stem cell transplantation. Current marketed IV busulfan formulations contain a Class 2 solvent (e.g., dimethylacetamide) that carries toxicity risks, including hepatotoxicity and neurotoxicity, prompting the FDA to recommend strict usage limits. GreenJay's reformulation aims to eliminate or reduce this harmful solvent, potentially offering a safer alternative that could expand the therapeutic window and improve patient outcomes in transplant procedures. The company leverages established drug chemistry and manufacturing processes to accelerate development, reducing technical risk relative to novel molecular entities. Founded in 2022, GreenJay is operating at the pre-clinical stage and has not yet disclosed total funding or valuation.

Upcoming Catalysts (preview)

• Q4 2026Completion of preclinical toxicity studies and selection of lead formulation75% success
• Q2 2027IND filing with FDA for phase 1 trial initiation40% success
• TBDStrategic partnership or licensing agreement for further development30% success